Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastic Drugs
- Alkylating Antineoplastics
- Antineoplastic Alkylating Agents
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Agents, Antineoplastic
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 2 | 5 |
| 1996 | 4 | 6 | 10 |
| 1997 | 7 | 5 | 12 |
| 1998 | 4 | 0 | 4 |
| 1999 | 5 | 6 | 11 |
| 2000 | 3 | 3 | 6 |
| 2001 | 10 | 5 | 15 |
| 2002 | 2 | 9 | 11 |
| 2003 | 6 | 7 | 13 |
| 2004 | 11 | 8 | 19 |
| 2005 | 8 | 2 | 10 |
| 2006 | 11 | 4 | 15 |
| 2007 | 7 | 5 | 12 |
| 2008 | 9 | 6 | 15 |
| 2009 | 10 | 7 | 17 |
| 2010 | 9 | 6 | 15 |
| 2011 | 7 | 4 | 11 |
| 2012 | 7 | 4 | 11 |
| 2013 | 10 | 3 | 13 |
| 2014 | 10 | 6 | 16 |
| 2015 | 9 | 6 | 15 |
| 2016 | 4 | 4 | 8 |
| 2017 | 7 | 3 | 10 |
| 2018 | 6 | 1 | 7 |
| 2019 | 5 | 3 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide. J Med Chem. 2024 Feb 22; 67(4):2425-2437.
-
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023 07 06; 25(7):1249-1261.
-
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors. Br J Cancer. 2023 08; 129(2):266-274.
-
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair. Adv Sci (Weinh). 2023 01; 10(3):e2205529.
-
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. Int J Mol Sci. 2022 Feb 11; 23(4).
-
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol. 2021 10 01; 23(10):1736-1749.
-
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021 06 01; 23(6):920-931.
-
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
-
Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proc Natl Acad Sci U S A. 2021 03 30; 118(13).
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.